Foghorn Therapeutics Inc. (FHTX) stock intrinsic value fair value estimate & owner earnings analysis

Foghorn Therapeutics is a clinical-stage biotechnology company built around a proprietary chromatin-regulation drug discovery platform. It has no approved products and generates no product sales; its only revenue comes from a 2021 research collaboration with Eli Lilly and Company, which paid Foghorn a $300 million upfront payment in January 2022 in exchange for rights to co-develop SMARCA2-targeted cancer drugs, including the company's lead product candidate, FHD-909, now in a Phase 1 trial in non-small-cell lung cancer and other solid tumors. Because none of Foghorn's drug candidates have completed clinical trials or received regulatory approval, we place no value on the pipeline itself in any of the three cases below -- an approach we apply uniformly to every early-stage biotech. A drug candidate's value only becomes real once trial results and approvals are actually in hand; until then it is not something we can value with confidence, even though the market clearly prices in some chance of success. This is a deliberately conservative lens: it treats Foghorn purely as its cash balance, minus the cost of running the business until that cash is used up. As of June 30, 2026, Foghorn held about $167.6 million in cash and marketable securities, no debt, and was spending cash from operations at roughly $86 million a year -- a level essentially unchanged from the prior fiscal year, after several years of falling spend (from $118 million in 2023 to $100 million in 2024 to $86 million in 2025). That decline partly reflects a hard lesson: Foghorn's own wholly-owned drug candidate, FHD-286, was discontinued in December 2024 after disappointing results in acute myeloid leukemia and uveal melanoma, and an earlier collaboration with Merck was also discontinued. Both are reminders that even a well-funded science platform can produce failures, which is exactly why we don't credit the remaining pipeline with any value beyond what's already proven. At the current spending pace, the cash on hand funds roughly 22-23 months of operations. The base case assumes spending holds near its current rate; discounted back at a flat 6%, the cash that will actually remain available to shareholders after paying for the research needed to keep the science alive during that runway nets out to a value only slightly above zero, around $0.15 per share. The bull case credits Foghorn with continuing the real, multi-year trend of shrinking its spending (as it has for three straight years), which extends the runway to a little over three years and pushes the value to roughly $0.20 per share. The bear case assumes spending reaccelerates toward the $99-110 million range last seen in 2022-2023 as ongoing programs advance, cash runs out closer to 19 months, and -- because Foghorn carries a real, non-cancelable office lease obligation of roughly $43 million that would still be owed even if operations were wound down early -- the bear outcome comes out negative, at roughly $(0.45) per share. None of these cases assigns any value to a successful drug approval, a future milestone payment from Lilly, or additional financing on favorable terms, because none of those are contracted or already earned -- they are simply not yet real. Given the binary, all-or-nothing nature of drug development, the margin-of-safety price reflects almost pure cash value with a wide safety margin -- around $0.08 per share. That view would change only if Foghorn's SMARCA2 program produces clinical data mature enough to materially de-risk approval, or if a collaboration amendment converts a currently contingent payment into one guaranteed regardless of trial outcome -- at that point, a portion of the pipeline could reasonably start to carry real value.